Athira Pharma (ATHA) Competitors $0.64 -0.02 (-3.02%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATHA vs. PASG, AGEN, ALGS, TLSA, COYA, IMUX, AVTX, ADAG, MIST, and ANIXShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Passage Bio (PASG), Agenus (AGEN), Aligos Therapeutics (ALGS), Tiziana Life Sciences (TLSA), Coya Therapeutics (COYA), Immunic (IMUX), Avalo Therapeutics (AVTX), Adagene (ADAG), Milestone Pharmaceuticals (MIST), and Anixa Biosciences (ANIX). These companies are all part of the "medical" sector. Athira Pharma vs. Passage Bio Agenus Aligos Therapeutics Tiziana Life Sciences Coya Therapeutics Immunic Avalo Therapeutics Adagene Milestone Pharmaceuticals Anixa Biosciences Athira Pharma (NASDAQ:ATHA) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends. Do analysts recommend ATHA or PASG? Athira Pharma presently has a consensus target price of $13.83, suggesting a potential upside of 2,054.72%. Passage Bio has a consensus target price of $9.00, suggesting a potential upside of 1,682.18%. Given Athira Pharma's higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than Passage Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Passage Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ATHA or PASG? Athira Pharma has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Which has stronger earnings & valuation, ATHA or PASG? Passage Bio is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$117.67M-$2.85-0.23Passage BioN/AN/A-$102.06M-$1.17-0.43 Is ATHA or PASG more profitable? Passage Bio's return on equity of -72.53% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -115.62% -88.94% Passage Bio N/A -72.53%-52.10% Does the MarketBeat Community prefer ATHA or PASG? Passage Bio received 31 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 68.00% of users gave Passage Bio an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformAthira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Passage BioOutperform Votes5168.00% Underperform Votes2432.00% Does the media prefer ATHA or PASG? In the previous week, Athira Pharma's average media sentiment score of 0.00 beat Passage Bio's score of -1.50 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Neutral Passage Bio Very Negative Do insiders & institutionals believe in ATHA or PASG? 57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 4.3% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryPassage Bio beats Athira Pharma on 8 of the 14 factors compared between the two stocks. Ad Colonial MetalsA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.83M$3.03B$5.23B$8.84BDividend YieldN/A1.86%5.54%4.08%P/E Ratio-0.2343.4993.1417.56Price / SalesN/A369.721,239.2791.27Price / CashN/A172.5641.4336.93Price / Book0.434.607.236.54Net Income-$117.67M-$41.63M$119.93M$226.15M7 Day Performance-4.19%2.57%2.14%3.77%1 Month Performance35.73%-2.91%-2.23%4.46%1 Year Performance-57.76%26.54%32.63%27.57% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma2.8132 of 5 stars$0.64-3.0%$13.83+2,054.7%-57.2%$24.83MN/A-0.2340Gap DownPASGPassage Bio2.6376 of 5 stars$0.54+3.9%$9.00+1,579.1%-17.6%$33.11MN/A-0.46130Negative NewsAGENAgenus3.8863 of 5 stars$2.86+7.1%$10.00+249.7%-75.4%$67.10M$156.31M-0.25389Analyst RevisionGap DownALGSAligos Therapeutics3.839 of 5 stars$19.68+8.1%$75.00+281.2%+17.9%$70.63M$15.53M-1.4990High Trading VolumeTLSATiziana Life Sciences0.5456 of 5 stars$0.97-3.0%N/A+68.5%$102.24MN/A0.008Positive NewsCOYACoya Therapeutics2.7652 of 5 stars$6.08+0.8%$16.67+174.1%+29.0%$101.60M$6M-9.356IMUXImmunic2.7017 of 5 stars$1.12+3.7%$12.25+998.7%+4.8%$100.44MN/A-0.9170Positive NewsAVTXAvalo TherapeuticsN/A$9.65-11.5%N/A-52.3%$100.26M$1.92M0.0040ADAGAdagene2.9036 of 5 stars$2.26+8.1%$5.00+121.2%+53.4%$100.05M$18.11M0.00260Positive NewsGap UpMISTMilestone Pharmaceuticals2.4782 of 5 stars$1.85-0.5%$12.00+548.6%-30.6%$98.66M$1M-2.3030Positive NewsANIXAnixa Biosciences2.8356 of 5 stars$3.06+0.7%$7.00+128.8%+11.9%$98.47M$210,000.00-7.855Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies PASG Competitors AGEN Competitors ALGS Competitors TLSA Competitors COYA Competitors IMUX Competitors AVTX Competitors ADAG Competitors MIST Competitors ANIX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHA) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
